The Clinical Study Of Therapying Malignant Pleural Or Peritoneal Effusions With Recombinant Mutant Human Tumor Necrosis Factor

Background: Malignant pleural and peritoneal effusions are the common complications of terminal cancer patients, effective and timely control of pleural and peritoneal effusions is of great importance in the overall treatment of terminal cancer patients. According to relevant references, recombinant mutant human tumor necrosis factor(rmh TNF) is effective in the treatment of malignant pleural and peritoneal effusions, which blazes a new path for effective clinical control of pleural and peritoneal effusions.Objective: Investigate the curative and side effects of perfusing rmh TNF in the treatment of pleural and peritoneal effusions.Methods: Objects who have been histopathologically and cytologically diagnosed as terminal cancer patients are selected according to the following conditions: the patients have middle volume of pleural or peritoneal effusions; ECOG scores range from 0 to 2; estimated survival time of the patients are above 3 months; hearts, livers, and kidneys of the patients are fully functional before treatment, and can be tolerant to chemotherapy, the patients’ body temperatures are normal; the patients have no history of drug allergy; the patients haven’t been through local chemotherapy in a month; the patients should know about this research and sign the medical informed consent. Pump out the pleural/peritoneal effusions as clear as possible, and inject rmh TNF to the pleural/peritoneal cavity at a dose of 300 million IUs per time(diluted with 30-50 ml saline water), administrate the drugs on the 1st, 4th, 7th, 10 th day, three or four times in all.Results: According to the WHO standard, 13 out of 15 patients of malignant pleural effusions were complete, the total response case was 9, and the total response rate was 69.23%. 16 out of the 18 patients of malignant peritoneal effusions were complete, the total response case was 10, and the total response rate is 62.50%. The side effects mainly include: acratia(3 cases), fever(2 cases), soreness(1 case), constipation(1 case), bone marrow suppression(1 case), the degrees are all quite low, which indicates a optimistic tolerability.Conclusion: Regional perfusion of rmh TNF is effective in the treatment of malignant pleural and peritoneal effusions, along with the low incidence of side effect, and the optimistic tolerability, it shows great prospect in the clinical application.